دورية أكاديمية
Identification of a Subset of Stage I Colorectal Cancer Patients With High Recurrence Risk.
| العنوان: | Identification of a Subset of Stage I Colorectal Cancer Patients With High Recurrence Risk. |
|---|---|
| المؤلفون: | Lee LH; Department of Pathology, University of British Columbia, Vancouver, BC, Canada.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Davis L; Department of Surgery, Albany Medical College, Albany, NY, USA.; Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Ylagan L; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Omilian AR; Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Attwood K; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Firat C; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shia J; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Paty PB; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cance WG; Department of Surgery, University of Arizona College of Medicine, Phoenix, AZ, USA. |
| المصدر: | Journal of the National Cancer Institute [J Natl Cancer Inst] 2022 May 09; Vol. 114 (5), pp. 732-739. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003-> : Cary, NC : Oxford University Press Original Publication: Bethesda, Md., U. S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health; Washington, for sale by the Supt. of Docs., U. S. Govt. Print. Off. |
| مواضيع طبية MeSH: | Colorectal Neoplasms*/pathology, Humans ; Immunohistochemistry ; Neoplasm Staging ; Prognosis ; Proportional Hazards Models |
| مستخلص: | Background: A challenge in early-stage colorectal cancer (CRC) is identifying biomarkers that predict an increased risk for recurrence. A potential clinically adaptable biomarker is focal adhesion kinase (FAK), a tyrosine kinase that promotes invasion and metastasis. Methods: An initial, single-institution, 298-patient cohort with all stages of CRC and long-term follow-up was assessed for FAK with tissue microarrays using immunohistochemistry. FAK expression was scored and dichotomized into high and low. Subsequently, a validation cohort of 517 early-stage CRCs from a separate institution was evaluated. All statistical tests were 2-sided. Results: FAK overexpression did not correlate with any known histologic feature and was an early event in CRC, increasing from normal colon to stage I, and stage I to II, but not different at higher stages. High FAK was associated with decreased 10-year recurrence-free survival (RFS) among stage I patients (70.2% for high FAK vs 94.1% for low, P = .02), but not among higher stages in the initial cohort. The same finding was seen in the validation cohort (73.1% for high FAK vs 93.1% for low, P = .004). Multivariable survival analysis for stage I patients showed only two statistically significant factors predicting RFS: FAK (hazard ratio = 5.27, 95% confidence interval = 1.81 to 15.33, P = .002) and perineural invasion (hazard ratio = 7.38, 95% confidence interval = 1.01 to 53.96, P = .049). FAK was the only statistically significant factor in multivariable analysis across RFS, overall, and disease-specific survivals. Conclusions: High FAK expression identified a subset of stage I CRC patients with high incidence of recurrence and reduced survival, suggesting that FAK has important prognostic value. These patients would immediately benefit from more rigorous surveillance protocols for recurrent disease. (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.) |
| References: | Arch Pathol Lab Med. 2000 Aug;124(8):1185-91. (PMID: 10923081) Nat Med. 2015 Nov;21(11):1350-6. (PMID: 26457759) Histol Histopathol. 2009 Apr;24(4):503-10. (PMID: 19224453) Ann Oncol. 2018 Nov 1;29(11):2240-2246. (PMID: 30247524) Gastroenterol Hepatol Bed Bench. 2013 Winter;6(1):6-13. (PMID: 24834238) Am J Pathol. 2007 Nov;171(5):1509-19. (PMID: 17982127) Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):90-6. (PMID: 19661787) Lancet. 1993 Oct 23;342(8878):1024-5. (PMID: 8105266) ANZ J Surg. 2016 Jan-Feb;86(1-2):49-53. (PMID: 26235683) Clin Cancer Res. 2000 Jun;6(6):2417-23. (PMID: 10873094) Eur J Surg Oncol. 2003 Sep;29(7):571-4. (PMID: 12943621) Eur J Surg Oncol. 2008 Nov;34(11):1253-61. (PMID: 18556171) Mod Pathol. 2012 Oct;25(10):1315-25. (PMID: 22790014) Int J Surg. 2018 Mar;51:71-75. (PMID: 29367039) Clin Cancer Res. 2003 Jan;9(1):215-22. (PMID: 12538472) Biomed Res Int. 2015;2015:690690. (PMID: 25918719) J Oncol Pract. 2017 Apr;13(4):233-241. (PMID: 28399381) Anticancer Res. 2014 Aug;34(8):3969-74. (PMID: 25075018) Arch Pathol Lab Med. 2014 Dec;138(12):1564-77. (PMID: 25427038) Int J Colorectal Dis. 2013 Jan;28(1):9-18. (PMID: 22733437) Cancer Res. 1995 Jul 1;55(13):2752-5. (PMID: 7796399) Am J Dermatopathol. 2015 Aug;37(8):593-603. (PMID: 26193707) Br J Cancer. 2014 Apr 15;110(8):2159-64. (PMID: 24642618) Anticancer Agents Med Chem. 2010 Dec;10(10):735-41. (PMID: 21214510) PLoS One. 2016 Sep 16;11(9):e0162666. (PMID: 27637100) Sci Signal. 2013 Mar 26;6(268):pe10. (PMID: 23532331) Transl Oncol. 2020 Nov;13(11):100836. (PMID: 32739842) Korean J Pathol. 2012 Oct;46(5):454-62. (PMID: 23136572) N Engl J Med. 2016 Jan 21;374(3):211-22. (PMID: 26789870) Nat Rev Cancer. 2005 Jul;5(7):505-15. (PMID: 16069815) Cell. 2015 Sep 24;163(1):160-73. (PMID: 26406376) |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS; P30 CA016056 United States CA NCI NIH HHS; P30 CA023074 United States CA NCI NIH HHS; S10 OD019977 United States OD NIH HHS |
| تواريخ الأحداث: | Date Created: 20220130 Date Completed: 20220511 Latest Revision: 20230131 |
| رمز التحديث: | 20230131 |
| مُعرف محوري في PubMed: | PMC9086771 |
| DOI: | 10.1093/jnci/djac023 |
| PMID: | 35094080 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1460-2105 |
|---|---|
| DOI: | 10.1093/jnci/djac023 |